The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Allogene Therapeutics Inc’s current trading price is -52.55% away from its 52-week high, while its distance from the 52-week low is 36.32%. The stock’s price range for this period has been between $2.01 and $5.78 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 1.34 million for the day, a number notably lower than the average daily volume of 2.13 million over the last three months.
Allogene Therapeutics Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $5.78 on 03/08/24, while the lowest price for the same period was registered at $2.01 on 07/05/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Allogene Therapeutics Inc (ALLO) has experienced a quarterly rise of 14.64% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 572.96M and boasts a workforce of 233 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.61, with a change in price of -0.24. Similarly, Allogene Therapeutics Inc recorded 2,501,075 in trading volume during the last 100 days, posting a change of -8.05%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for ALLO stands at 0.18. Similarly, the long-term debt-to-equity ratio is also 0.17.
ALLO Stock Stochastic Average
As of today, Allogene Therapeutics Inc’s raw stochastic average for the last 50 days stands at 59.77%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 50.31%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 40.67% and 36.85%, respectively.
ALLO Stock Price Performance Analysis
The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. This year’s metric has recorded a Price decrease of -14.64%. However, over the past six months, we’ve seen a stronger performance of -33.33%. The price of ALLO fallen by 10.48% over the last 30 days. And in the last five days, it has surged by 2.62%.
